PDPL

Trading in the equity shares of Parenteral Drugs (India) Limited (PDPL) shall remain suspended pursuant to intimation received from the Company. As per Resolution Plan the existing equity shares of the Company shall stand delisted with Nil payment. For the detailed corporate announcement submitted by the Company please refer the Exchange website.

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange regarding Committee Meeting to be held on August 12, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on August 09, 2024.

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on July 12, 2024.

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on Jun 07, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Committee Meeting to be held on Jun 07, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on May 29, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Prior Intimation of COC'.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on May 14, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on May 11, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on April 24, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Prior Intimation of the 10th Meeting of Committee of Creditors ( CoC ) of Parenteral Drugs (India) Ltd., the Corporate Debtor Scheduled on Wednesday, 24th April, 2024 at 03:00 PM.'.

Parenteral Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on March 26, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on March 14, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Committee Meeting to be held on March 14, 2024.

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Post-Facto Intimation of the publication of Form G of Parenteral Drugs (India) Ltd., the Corporate Debtor which was published on Sunday, 21st January, 2024.'.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on January 19, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Committee Meeting held on January 15, 2024.

Parenteral Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Parenteral Drugs (India) Limited has informed the Exchange regarding 'Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and in accordance with the requirements of sub- clause 16(c) of Clause A of Part A of Schedule III of Listing Regulations, I would like to inform you that the Hon'ble NCLT, Mumbai Division Bench Court I vide the order dated 17.10.2023 (a certified copy of order was received on 27.10.2023) passed an order of replacement of Interim Resolution Professional Mr. Kairav Trivedi to Mr. Prawincharan Prafulchara

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution ProcessSubject: 1st COC meetingThis is to inform you that the 1st Meeting of Committee of Creditors of Parenteral Drugs (India) Limited Under CIRP will be held on 13/03/2023 at 4:30 PM through video conference / other audio-visual method.

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution ProcessSubject: Formation of COCThis is to inform you that, the Committee of Creditors of Parenteral Drugs (India) Limitedunder CIRP has been formed as on 03/03/2023, and same has been informed to Hon ble NCLT.

Parenteral Drugs (India) Limited has informed the Exchange about Corporate Insolvency Resolution ProcessSubject: List of CreditorsThis is to inform you that, the list of Creditors of Parenteral Drugs (India) Limited Under CIRP has been prepared on 03/03/2023 and uploaded in IBBI Website on 04/03/2023 and the same has been informed to Hon ble NCLT.

Parenteral Drugs (India) Limited has informed the Exchange about Public Announcement as per Corporate Insolvency Resolution Process

Parenteral Drugs (India) Limited has informed the Exchange about initiation of Corporate Insolvency Resolution Process against the Company

Parenteral Drugs (India) Limited has informed the Exchange about communication to shareholders as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding update on the operations of the Company.

Parenteral Drugs (India) Limited has informed the Exchange about resignation of Pooja Choukse as Company Secretary of the company w.e.f. 31-Jul-2022.

Parenteral Drugs (India) Limited has informed the Exchange about communication to shareholders as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 about the resignation of Ms. Pooja Choukse as a Company Secretary and Compliance Officer of the Company with effect from 31.07.2022.

Parenteral Drugs (India) Limited has informed the Exchange about Closure of trading window

PDPL : The Exchange had sought clarification from Parenteral Drugs (India) Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed.

PDPL : The Exchange has sought clarification from Parenteral Drugs (India) Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.

Parenteral Drugs (India) Limited has informed the Exchange about related party transaction for the period ended March 2022

Parenteral Drugs (India) Limited has informed the Exchange about Newspaper Advertisements for Annual Audited Financial Results for the Quarter and Financial Year ended on 31st March, 2022.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2022.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2022.

Parenteral Drugs (India) Limited has informed the Exchange about Board Meeting held on 30-May-2022 to consider financial statements for the period ended March 2022 and Other business matters

Parenteral Drugs (India) Limited has informed the Exchange about Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participant) Regulation, 2018

Promoter/Promoter Group of Parenteral Drugs (India) Limited has submitted a disclosure under Regulation 31(4) of SEBI Takeover Regulations for the year ended 31-Mar-2022